Catherine Hollingsworth

GlycoMimetics Reaping $38M for Phase II Sickle-Cell Effort

Oct. 22, 2009

By Catherine Hollingsworth

Unigene Hands Tarsa Phase III Asset as $24M Series A Closes

Oct. 21, 2009

By Catherine Hollingsworth

'Lux' with Luveniq: $50M Raise, Uveitis NDA Target Year's End

Oct. 20, 2009

By Catherine Hollingsworth

Targacept Wows Wall Street With Phase IIb Depression Data

Oct. 19, 2009

By Catherine Hollingsworth

Targacept wowed analysts with newly released Phase IIb data for depression drug candidate TC-5214, making a big splash at a meeting of the Society for Neuroscience and causing shares in the company to shoot up 16percent Friday. (BioWorld Today)

NewCo News: From A to III: Curemark Begins Late-Stage Autism Drug Trials

Oct. 16, 2009

By Catherine Hollingsworth

Ziopharm Phase II Sarcoma Trial Reaches Goal Early

Oct. 15, 2009

By Catherine Hollingsworth

Corcept Raising $18M to Push Corlux Through Final Testing

Oct. 14, 2009

By Catherine Hollingsworth

Lexicon's $48M Haul to Fund Phase IIs: Diabetes, IBS, More

Oct. 12, 2009

By Catherine Hollingsworth

Merck-dumped Paratek Woos Novartis: $485M Antibiotic Deal

Oct. 9, 2009

By Catherine Hollingsworth

Privately held Paratek Pharmaceuticals Inc. has found another partner to help develop its antibiotic PTK 0796 for life-threatening infections, this time joining with Swiss drugmaker Novartis AG in a deal valued at up to $485 million. (BioWorld Today)